Latest Rosuvastatin Stories

TRILIPIX has now been studied in combination with the most commonly used doses of rosuvastatin calcium (5 mg, 10 mg, 20 mg) in patients with mixed dyslipidemia ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Data from a new study showed that Abbott's TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints. TRILIPIX 135 mg in combination with rosuvastatin calcium 5 mg significantly improved HDL cholesterol...

Statin drugs, used by millions to reduce cholesterol levels and avoid heart disease, can reduce the possibility of blood clots that can form in the legs or lungs, a huge study announced on Sunday.The study gives a new motive for those with regular cholesterol to think about taking Crestor, Lipitor and Zocor, doctors' state.It was shown that Crestor reduced about half the chances of blood clots in those with low cholesterol but who had high inflammation. The study also showed that Crestor...

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP). This analysis was presented today at the 58th Annual American College of Cardiology Scientific Sessions (ACC) in Orlando, Florida, and...

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Results from a new sub- analysis of the JUPITER study show that patients with low to normal cholesterol levels and elevated high sensitivity C-reactive protein (hsCRP) who attained a dual treatment target of LDL-C <70mg/dL and hsCRP <2mg/L with CRESTOR(R) (rosuvastatin calcium) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%; p=0.033). These new data were presented...

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP). This analysis was presented today at the 58th Annual American College of Cardiology Scientific Sessions (ACC) in Orlando, Florida, and...

- Journal of Clinical Lipidology publishes largest study comparing cancer risk of ezetimibe and ezetimibe/simvastatin to statin therapies using FDA database - BOSTON, March 25 /PRNewswire-USNewswire/ -- A new study shows no increased cancer risk with ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to cancer rates of other powerful lipid-lowering statin therapies. The study, conducted by Tufts Medical Center lipid and health policy experts, was published in the...

More than 6 million heart patients might benefit from statins to prevent heart attacks and strokes, U.S. researchers said. Dr. Erin D. Michos of The Johns Hopkins University School of Medicine said about half of all cardiovascular events occur in patients who don't have high cholesterol and about 20 percent of these events occur in people who have no identifiable cardiovascular disease risk factor. The researchers built on the research at Brigham and Women's Hospital in Boston that found...

Percentage of Clinicians Performing hsCRP Testing Will Increase Dramatically Over the Next Six Months, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, as a result of the JUPITER clinical trial, 65 percent of surveyed managed care organizations' (MCO) pharmacy directors say they will reimburse AstraZeneca's Crestor for...

SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study presented today at the International Stroke Conference (ISC) in San Diego, California describes details of the stroke data according to gender, ethnicity and baseline risk factors. This data adds to the primary analysis of the JUPITER study which demonstrated that CRESTOR(R) (rosuvastatin calcium) 20mg significantly reduced the risk of stroke by nearly half (48%; p=0.002), compared to placebo among men and...

American Heart Association rapid access journal report: Study highlights: A new analysis estimates more than 11 million older Americans could be newly eligible for statin therapy if findings from the JUPITER trial are adopted into guidelines.That could take the number of older adults eligible for statin therapy to over 44 million, or 80 percent of that population.The analysis highlights a public health challenge since, even under current treatment guidelines, fewer than half of older...